Exploiting cancer cell cycling for selective protection of normal cells.
about
Protecting the normal in order to better kill the cancerCurtailing side effects in chemotherapy: a tale of PKCδ in cisplatin treatmentNeem components as potential agents for cancer prevention and treatmentTargeting of Chk2 as a countermeasure to dose-limiting toxicity triggered by topoisomerase-II (TOP2) poisonsPersistence to anti-cancer treatments in the stationary to proliferating transition.Fasting and cancer treatment in humans: A case series report.Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic indexFasting and differential chemotherapy protection in patientsDifferential effects of lovastatin on cisplatin responses in normal human mesothelial cells versus cancer cells: implication for therapy.Upregulation of survivin in G2/M cells and inhibition of caspase 9 activity enhances resistance in staurosporine-induced apoptosis.Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell cultureRecent progress in targeting cancer.Killing cells by targeting mitosisNCI's provocative questions on cancer: some answers to ignite discussion.An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells.CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy.Wt p53 impairs response to chemotherapy: make lemonade to spare normal cellsModelling of the cancer cell cycle as a tool for rational drug development: A systems pharmacology approach to cyclotherapy.Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions.Integrated experimental and simulation study of the response to sequential treatment with erlotinib and gemcitabine in pancreatic cancer.Short-term calorie and protein restriction provide partial protection from chemotoxicity but do not delay glioma progression.p53-Based cyclotherapy: exploiting the 'guardian of the genome' to protect normal cells from cytotoxic therapy.Inhibition of CDK4/6 protects against radiation-induced intestinal injury in mice.DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine.Toward a universal treatment for cancer: cell inflation assisted chemotherapy.Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitorsCyclotherapy: opening a therapeutic window in cancer treatment.Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy.Pharmacological manipulation of the cell cycle and metabolism to protect normal tissues against conventional anticancer drugs.The Levels of Oxidative Stress Biomarkers in Rats as a Response to Different Techniques of Testicular Biopsy.Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity.Antitumoral effects of cyclin-dependent kinases inhibitors CR8 and MR4 on chronic myeloid leukemia cell linesEpidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy.The use of the NEDD8 inhibitor MLN4924 (Pevonedistat) in a cyclotherapy approach to protect wild-type p53 cells from MLN4924 induced toxicity.Cell cycle checkpoint status in human malignant mesothelioma cell lines: response to gamma radiation.Protecting normal cells from the cytotoxicity of chemotherapy.Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion.
P2860
Q26801291-4EE7BC4F-F2F6-4C3D-9BB6-AAD76CAC3584Q26823867-C593FD78-0523-4A17-AECF-60DB41621DCFQ26995699-54AAF5C7-8725-4D72-B7DA-3462D6FA6850Q28828183-6CB5ECAB-121B-4DC1-A976-03709DE5CEA9Q30834504-8B6E8E9D-75E5-4522-AD09-82455FFFD59CQ33627959-7725C67E-5E51-4CA6-A086-CF2CD9D232BCQ33718131-2027490C-B84D-4173-9E68-13C1BC5658F3Q34024755-EA1CA46A-19A3-485F-B282-6F00127AF7ABQ34428844-9E913931-3DB5-475E-AACF-D81F12430575Q35191266-04F1E8E6-A586-4476-A1F3-79EA7CD5E80CQ35679387-CA7E0210-978E-49A9-B48C-346B8EA95326Q35740782-60394495-B402-46B7-A8FD-C6EF1D3A276CQ35754713-C24059EE-D6CF-4EDE-B6C4-98857B6423B8Q35764401-BE59A04A-55B5-4B5E-A48C-B4524355B407Q36023740-9E2724B1-C8F0-449F-9D6E-BB5D34864298Q36130084-0AEF5BB4-8F16-4A19-9A36-AD327FD4AFFBQ36234051-D21CF783-DBCD-4822-A53B-3900DE77116FQ36361812-8972D1C2-69DA-4369-9201-98BB0B3D0E24Q36926148-63454675-F1DB-42B1-AEED-4A3C88448E3FQ37085804-D29EAF7C-46CE-4447-AB5A-58A5F5380261Q37146692-0984A8F1-A3C1-4BF4-9BCF-7588666977DCQ37385293-5491455C-4240-44A6-9580-0890254BEE0EQ37395807-796A32F2-9CB0-4F0D-8DAB-3665D34F8988Q37619866-0B6CAA09-2DE0-4692-B1AE-DC67C4BA541BQ38155169-15E5EEC7-F961-475F-AF4C-523686D7A3DEQ38261022-353D85DF-8EFA-404C-86DA-56239FF5674CQ39328882-C38D70AE-AC7A-4340-8E02-866E7866F10BQ39593069-B5CDF078-8835-4C0C-8058-1D51E34A895DQ40048622-921BDB80-31B5-4099-B8B5-8AB62C701BC0Q40146596-0AD0DA15-F78A-4E6F-AEB2-83634678AA8BQ41561051-3789E2F7-142F-49F1-95F4-01D224739B1CQ41724012-48E2F6B5-A1E7-4E9C-B28F-D924A6765AA0Q41859828-5F09F3B2-FC68-4DD0-8195-6B25CD2BEC8FQ42361441-03DB2A06-A192-4708-80C6-FF0F44D91F14Q42560724-5438B1FB-7AE3-4C01-A291-9CE06853E480Q43205975-D120C536-A12E-4827-8955-2C7386F8E598Q48227806-2CAD1C8A-A30E-4451-909F-E42D9066C1C8
P2860
Exploiting cancer cell cycling for selective protection of normal cells.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Exploiting cancer cell cycling for selective protection of normal cells.
@ast
Exploiting cancer cell cycling for selective protection of normal cells.
@en
Exploiting cancer cell cycling for selective protection of normal cells.
@nl
type
label
Exploiting cancer cell cycling for selective protection of normal cells.
@ast
Exploiting cancer cell cycling for selective protection of normal cells.
@en
Exploiting cancer cell cycling for selective protection of normal cells.
@nl
prefLabel
Exploiting cancer cell cycling for selective protection of normal cells.
@ast
Exploiting cancer cell cycling for selective protection of normal cells.
@en
Exploiting cancer cell cycling for selective protection of normal cells.
@nl
P1433
P1476
Exploiting cancer cell cycling for selective protection of normal cells
@en
P2093
Blagosklonny MV
P304
P407
P577
2001-06-01T00:00:00Z